We are live on
!
Find out more
Alnylam Pharmaceuticals
ALNY
ALNY
197 hedge funds and large institutions have $3.73B invested in Alnylam Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 69 increasing their positions, 65 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
200% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 15
17% more funds holding
Funds holding: 168 → 197 (+29)
6% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 65
4% more capital invested
Capital invested by funds: $3.58B → $3.73B (+$155M)
53% less call options, than puts
Call options by funds: $27.9M | Put options by funds: $59.7M
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Holders
197
Holders Change
+29
Holders Change %
+17.26%
% of All Funds
5.69%
Holding in Top 10
1
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-75%
% of All Funds
0.03%
New
45
Increased
69
Reduced
65
Closed
15
Calls
$27.9M
Puts
$59.7M
Net Calls
-$31.9M
Net Calls Change
-$27.9M
Top Buyers
| 1 |
Franklin Resources
San Mateo,
California
|
+$35.2M |
| 2 |
GTP
Global Thematic Partners
New York
|
+$33M |
| 3 |
CCI
Columbus Circle Investors
|
+$26.8M |
| 4 |
DM
Deerfield Management
New York
|
+$23.4M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$13.9M |
Top Sellers
| 1 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
-$78M |
| 2 |
AWG
Alpha Wave Global
New York
|
-$64.3M |
| 3 |
SPC
Slate Path Capital
New York
|
-$45.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$22.1M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$17M |
